Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ILLUMINATE-C
2023-503382-29-00Phase 3Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- May 2023
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 12
01
Overview
Phase 3, open-label trial of lumasiran in Primary Hyperoxaluria Type 1 (PH1) (2 cohorts), sponsored by Alnylam Pharmaceuticals. Primary endpoints: Cohort A: Percent change in plasma oxalate from baseline to Month 6 and Cohort B: Percent change in plasma oxalate from baseline to Month 6. Started May 2023; status: completed.
02
Drugs
lumasiran
03
Conditions
Primary Hyperoxaluria Type 1 (PH1)
Beyond the preview
Go deeper on 2023-503382-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503382-29-00.